# NUDT15

Source: https://onco.cc/targets/nudt15/  
OnCo record `nudt15` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NUDT15 (Nucleotide triphosphate diphosphatase NUDT15) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it.

## Summary

Catalyses the hydrolysis of nucleoside triphosphates including dGTP, dTTP, dCTP, their oxidised forms like 8-oxo-dGTP and the prodrug thiopurine derivatives 6-thio-dGTP and 6-thio-GTP. Could also catalyse the hydrolysis of some nucleoside diphosphate derivatives. Hydrolyses oxidised nucleosides triphosphates like 8-oxo-dGTP in vitro, but the specificity and efficiency towards these substrates are low.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Mercaptopurine, Thioguanine and Azathioprine. In OnCo, 1 product record names it (Mercaptopurine).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: nudix hydrolase 15; Nucleotide triphosphate diphosphatase NUDT15; MTH2; FLJ10956
- Tags: cancer-genes-wave
- Symbol: NUDT15
- Class: enzyme
- Biology: Catalyses the hydrolysis of nucleoside triphosphates including dGTP, dTTP, dCTP, their oxidised forms like 8-oxo-dGTP and the prodrug thiopurine derivatives 6-thio-dGTP and 6-thio-GTP. Could also catalyse the hydrolysis of some nucleoside diphosphate derivatives. Hydrolyses oxidised nucleosides triphosphates like 8-oxo-dGTP in vitro, but the specificity and efficiency towards these substrates are low. Therefore, the potential in vivo sanitising role of this enzyme, that would consist in removing oxidatively damaged forms of nucleosides to prevent their incorporation into DNA, is unclear. Through the hydrolysis of thioguanosine triphosphates may participate in the catabolism of thiopurine drugs. May also have a role in DNA synthesis and cell cycle progression by stabilising PCNA. Locus 13q14.2 (HGNC).

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Childhood Acute Lymphocytic Leukaemia.

## Sources

- HGNC HGNC:23063: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23063
- UniProt Q9NV35: https://www.uniprot.org/uniprotkb/Q9NV35/entry
- NCBI Gene 55270: https://www.ncbi.nlm.nih.gov/gene/55270
- Ensembl ENSG00000136159: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136159

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- drugs: [Mercaptopurine](https://onco.cc/drugs/mercaptopurine/)

---
JSON: https://onco.cc/api/v1/entities/nudt15.json